2014. október 16. New York-palota, Fehér-Vörös Szalon
1073 Budapest, Erzsébet körút 9–11. ...

Melanoma and colorectal cancer are the main field of progress
Johann de Bono
ESMO 2014
Scientific Chair...

Jean-Pascal Machiels, Belgium...

Thymidylate synthase is one of the proteins that is targeted by pemetrexed which is the most widely used chemotherapeutic regimen in the treatment of non-squamous NSCLC,” explains study author Professor Myung-Ju Ahn, from the Section of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. “In this study, we tried to evaluate whether expression of thymidylate synthase is a predictive ...

The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The researchers showed that 38.7% of these people had high-risk adenomas --meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia....

At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea. “We wanted to conduct this study because pemetrexed plus platinum chemotherapy is the most commonly used regimen for treating patients with non-squamous...

Floriana Morgillo, ESMO Expert on Lung Cancer...

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.

Coordinated action is needed at an international level to ensure new cancer-fighting ...

More than 70% of young, European cancer specialists are showing signs of burnout, the largest survey of its kind has revealed. The results, reported at the Congress of ESMO 2014 in Madrid, have prompted calls for serious action to address the issue at all levels. ...

Dr Felipe Ades Moraes from Institut Jules Bordet in Brussels, Belgium and colleagues presented their disappointing findings on trastuzumab access in Eastern-Europe at ESMO 2014 Congress in Madrid, Spain. The authors found that patients in Eastern Europe had less access to the HER2 positive breast cancer targeted drug trastuzumab than their counterparts in Western Europe and the USA; differences they say can be linked to discrepancies in cancer ...

Online edukációs modulunkban Prof. Dr. İbrahim Haznedaroğlu a törökországi Hacettepe Egyetem professzora tart előadást a European LeukemiaNet aktuális irányelveiről. A professzor részt vett az ELN tavalyi guideline-jának összeállításában, szakmai munkássága elsősorban a CML kutatására összpontosul.
A modul lehetőséget ad az előadás egyes részfejezetei közötti navigálásra, így a teljes prezentáció ...

Bár a metasztatikus prosztatarák ma még gyógyíthatatlan betegség, de a sugárfizika és a radiokémia fejlődésének köszönhetően a közelmúltban a betegek életét és életminőségét igazoltan növelő új radioizotópos kezelés vált elérhetővé. A Ra-223-diklorid izotópot tartalmazó Xofigo injekciót Debrecenben 3 beteg kapta meg először. A jelentős előrelépést mutató terápia kapcsán Urbancsek Hilda, Garai Ildikó, ...